Basel, Switzerland and Cambrige, MA-based CRISPR Therapeutics has named Marc Becker its chief financial officer. Becker is coming off a stint as senior vice president and CFO of rEVO Biologics—where he helped prep the company for its 2014 IPO—and was a finance executive at Genzyme before that. CRISPR Therapeutics is one of three companies with operations in the Boston area, along with Editas Medicine (NASDAQ: [[ticker:EDIT]]) and Intellia Therapeutics, that are developing therapeutics based on the CRISPR-Cas9 gene editing system. Editas is the only one of the three to go public as of yet.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler